IL-4

Interleukin 4, B-cell stimulatory factor

human, recombinant, E. coli

Product Cat. No. Amount Price (EUR) Buy / Note
IL-4 PR-463 20 μg 253,00 Add to Basket/Quote Add to Notepad

For in vitro use only!

Shipping: shipped at ambient temperature

Storage Conditions: store at -20 °C
avoid freeze/thaw cycles

Shelf Life: 12 months

Molecular Weight: 15 kDa

Accession number: P05112

Accession number: P05112

Purity: > 95 % (SDS-PAGE, RP-HPLC)

Form: lyophilized

Solubility: It is recommended to reconstitute the lyophilized IL-4 in bidest H2O not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

Activity: ED50: < 0.2 ng/ml, corresponding to a specific activity of 5 x 105 IU/mg, determined by the dosedependent stimulation of TF-1 cells.

Description:
The anti-inflammatory cytokine Interleukin-4 is involved in the regulation of inflammatory responses by promoting the differentiation of naïve T-cells to T helper type 2 (Th2) cells. A key anti-inflammatory action of IL-4 results from its ability to inhibit the release of pro-inflammatory cytokines by innate immune cells and to upregulate the synthesis of IL-1 receptor antagonist. IL-4 has been demonstrated to be a potent cofactor for B and T lymphocyte proliferation and differentiation. Recombinant human IL-4 produced in E. coli is a single, non-glycosylated form of human IL-4 polypeptide chain containing 130 amino acids and having a molecular mass of 15 kDa. IL-4 is purified by proprietary chromatographic techniques.

Endotoxin: Less than 0.1 ng/μg (IEU/μg) of IL-4.

Selected References:
Wurster et al. (2002) Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of BclxL. J. Biol. Chem. 277:27169.
Nolan et al. (2004) Role of interleukin-4 in regulation of age-related inflammatory changes in the hippocampus. J. Biol. Chem. 280:9354.
Petersen et al. (2002) Optimisation of the CT h4S bioassay for detection of human interleukin-4 secreted by mononuclear cells stimulated by phytohaemaglutinin or by human leukocyte antigen mismatched mixed lymphocyte culture. Immunol. Lett. 84:29.
Whitehead et al. (2002) Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. J. Immunother. 25:352.
Ekerfelt et al. (2002) Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro: comparison of ELISPOT, a novel ELISA and real-time RT-PCR. J. Immunol. Methods. 260:55.
Casolaro et al. (2000) Identification and characterization of a critical CP2-binding element in the human interleukin-4 promoter. J. Biol. Chem. 275:36605.
Davis et al. (2000) A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer. Growth Factors. 17:287.
Okada et al. (2000) Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virusthymidine kinase for glioma tumor vaccine therapy. Cancer Gene Ther. 7:486.